you're too smart for me to follow. could you give your predication in the following form?
thanks for the reminder.
I started thinking in terms of mnk after the merge. mnk ended last year at $99. we're already 8% up this year. my goal is to have a 20% gain this year. look very promising.
it's important to note that the ceo made it clear (to me anyway) that this is not going to impact other opportunities (acquisitions). very strong cash position.
just put all the jerrynnn on ignore. the original was a joke. the rest are just as low.
"The TKM-HBV Phase I clinical trial is a randomized, single-blind, placebo-controlled study, involving single ascending doses of TKM-HBV. The study will assess the safety, tolerability and pharmacokinetics of intravenous administration of two formulations of TKM-HBV in healthy adult subjects. For each formulation, there are five planned cohorts for a total of 20 subjects (40 in total for both formulations). Four subjects will be enrolled per cohort with three subjects receiving TKM-HBV, and one receiving placebo."
Interesting. but arwr is well ahead of the game.
thanks again, pj. I've got used to the small(?) swings. that won't scare me. I am concerned with a crash many are talking about, something in the mag of 20% to 30%. that would be devastating.
gild seems a bit more transparent nowadays, as the numbers are closely followed by the board and the earnings are correlated. It appears the mnk numbers are hard to tell, with the gel plays part of the game only.
i agree with you that gild could be more volatile. for some reason, i also feel it has more risk than mnk (don't know why i had the feeling). i might just give up all the gild (feels bad, as it took me quite some energy to build the current holding). oh well. still in green.